Clinical trials: Severe Pneumonia
Sars-CoV2, Symptomatic Condition
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine…
- Conditions
- Sars-CoV2, Symptomatic Condition, Covid-19
- Trial name
- PRECISE (NCT04351191)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 4 sites in Pakistan
- Volunteers
- 137 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
COVID-19 Pneumonia
The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients
Coronavirus Disease 19 (COVID-19) is a worldwide pandemic and a major global health concern which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04884490
- Testing
- Co-trimoxazole
- Where
- Bangladesh
- Volunteers
- 94 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
COVID-19, SARS-CoV-2
Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.
Translational, prospective / retrospective, non-profit, non-pharmacological study, with cohort characteristics. The study consists of two parts: the first to study epidemiological aspects of the spread of the disease and the…
- Trial name
- CORSA (NCT04345315)
- Testing
- serological test, Rapid molecular test, Next generation Sequencing (NGS) analysis
- Where
- 2 sites in Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Covid19
Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection)
The main objective of this part of the project is to identify the germline genetic factors which discriminate the benign and severe forms of SARS-CoV2 (CoVID-19) infection in the context of the ongoing SARS-CoV2 (HCOVID-19)…
- Trial name
- COVIDGEN (NCT04644146)
- Testing
- GENETIC
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Covid19
Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study
An observational, retrospective, classic cohort study of adult patients hospitalized for severe pneumonia with a diagnosis of SARS-CoV-2 by RT-PCR will be carried out.
- Trial name
- NCT04954235
- Where
- Argentina
- Volunteers
- 847 people
- Sponsor
- Inmunova S.A.
SARS-CoV-2, SARS-CoV Infection
Sero-prevalence COVID-19 Among Belgian Children
Based on studies in China, Iceland, the Netherlands and Italy it seems that children are less affected by SARS-CoV-2 infections and play a lesser role in the dissemination of the SARS-CoV-2 virus.
- Conditions
- SARS-CoV-2, SARS-CoV Infection, Covid19
- Trial name
- SeCoBelChild (NCT04613817)
- Where
- Belgium
- Volunteers
- 2,103 people, healthy volunteers welcome
- Sponsor
- Sciensano
Infectious Pneumonia, Severe COVID-19
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Primary objective: To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
- Trial name
- NCT05254990
- Testing
- Reparixin
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 414 people
- Sponsor
- Dompé Farmaceutici S.p.A
Pneumonia, Postoperative Complications
Postoperative Pulmonary Complications in Elderly Patients Undergoing Major Abdominal Surgery
This study aims to identify the risk factors associated with postoperative pulmonary complications (PPCs) in patients aged 65 years and older who undergo major abdominal surgery.
- Trial name
- PPC65MAS (NCT07306897)
- Where
- Turkey (Türkiye)
- Volunteers
- 239 people
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Coronavirus Disease (COVID-19), COVID-19
Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19
Retrospective study from November 2019 -Febrauary 2020 on severe respiratory illness to access the presence or absence of COVID-19 in patients samples by real-time PcR
- Trial name
- Explore (NCT04346056)
- Where
- 2 sites in Egypt
- Volunteers
- 500 people
- Sponsor
- Ain Shams University
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Covid19, SARS-CoV Infection
IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation
The purpose of this Pilot Study is to establish a hypothesis of whether or not intravenous immunoglobulin (IVIG) may impact the hospital length of stay, if started within 48 of mechanical ventilation in patients infected with…
- Trial name
- NCT04616001
- Testing
- IVIG
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sharp HealthCare
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
SARS (Severe Acute Respiratory Syndrome), Cytokine Storm
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure.
- Conditions
- SARS (Severe Acute Respiratory Syndrome), Cytokine Storm, ARDS, Human, COVID-19
- Trial name
- COVID-19-HBO (NCT04327505)
- Testing
- Hyperbaric oxygen
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 34 people
- Sponsor
- Karolinska Institutet
Coronavirus, COVID-19
Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it.
- Conditions
- Coronavirus, COVID-19, SARS-CoV Infection, Respiratory Failure
- Trial name
- CYCOV (NCT04324528)
- Testing
- vv-ECMO + cytokine adsorption (Cytosorb adsorber), vv-ECMO only (no cytokine adsorption)
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Dr. Alexander Supady
Berberine, COVID-19
The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19
Coronavirus disease 2019 (COVID-19) rapidly spread across China and throughout the world, causing hundreds of thousands died. Studies had shown that "cytokine storms" and subsequent multiple organ dysfunction (MODS) are important…
- Trial name
- BOIFIM (NCT04479202)
- Testing
- Berberine, Montmorrillonite
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Chinese Medical Association
COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2
Communication in ICU During COVID-19
This study explores the actual situation of communication during the Coronavirus disease 2019 (COVID-19) pandemic in the South Asia and Middle East region.
- Conditions
- COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04602351
- Testing
- Communication
- Where
- United Arab Emirates
- Volunteers
- 296 people
- Sponsor
- NMC Specialty Hospital
Deep Venous Thrombosis
Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology
Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio…
- Trial name
- VT-Covid-19 (NCT04452422)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Covid19, Corona Virus Infection
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC)…
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS
- Trial name
- ULSC (NCT04494386)
- Testing
- Umbilical Cord Lining Stem Cells (ULSC)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Restem, LLC.
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
2019 Novel Coronavirus Pneumonia, COVID-19
Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19
The novel coronavirus pneumonia is a kind of new emerging respiratory infectious disease, characterized by fever, dry cough, and chest tightness, and caused by the infection of the 2019 novel coronavirus (2019-nCoV).
- Trial name
- NCT04273646
- Testing
- UC-MSCs
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.